Abstract:We aimed to evaluate the expression of microRNA-182 (miR-182) in triple-negative breast cancer (TNBC) tissues and the TNBC cell line MDA-MB-231 and to investigate the effects of mirR-182 on the cellular behavior of MDA-MB-231 and the expression of the target gene profilin 1 (PFN1), thus providing new methods and new strategies for the treatment of TNBC. Quantitative real-time PCR (qRT-PCR) was utilized to evaluate the expression of miR-182 in TNBC tissues, relatively normal tissues adjacent to TNBC and the TNBC cell line MDA-MB-231. Forty-eight hours after the MDA-MB-231 cells were transfected with the miR-182 inhibitor, qRT-PCR was utilized to detect the changes in miR-182 expression levels, and an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was utilized to determine the effects of miR-182 on cell viability. Flow cytometry was adopted to determine whether miR-182 affects the proliferation rates and apoptosis levels of the MDA-MB-231 cells. The transwell migration assay method was used to investigate the effects of miR-182 on the migration of the MDA-MB-231 cells. A luciferase reporter gene system was applied to validate that PFN1 was the target gene of miR-182. Western blot was used to measure the effects of miR-182 on the PFN1 protein expression levels in the cells. qRT-PCR results showed that compared with the relatively normal tissues adjacent to TNBC, miR-182 expression was significantly increased in the TNBC tissues and the MDA-MB-231 cells (p<0.01). Compared with the control group, MDA-MB-231 cells transfected with the miR-182 inhibitor and incubated for 48 h showed significantly decreased miR-182 expression (p<0.01). The results of an MTT assay showed that inhibition of miR-182 in MDA-MB-231 cells led to significantly reduced cell viability (p<0.05). Flow cytometry analysis indicated that inhibition of miR-182 expression resulted in significantly decreased cell proliferation (p<0.05) and significantly increased levels of apoptosis (p<0.05). The results of a transwell migration assay showed that after inhibited of miR-182 expression, the number of cells passing through the transwell membranes was significantly decreased (p<0.05). The results from a luciferase reporter gene system showed that compared with the control group, the relative luciferase activity of the group transfected with the miR-182 inhibitor was significantly increased (p<0.05). Western blot analysis showed that compared with the control group, PFN1 protein expression levels were significantly increased in the MDA-MB-231 cells transfected with the miR-182 inhibitor and incubated for 48 h (p<0.05). In conclusion, miR-182 is upregulated in TNBC tissues and cells. It promotes the proliferation and invasion of MDA-MB-231 cells and could negatively regulate PFN1 protein expression. Treatment strategies utilizing inhibition of miR-182 expression or overexpression of the PFN1 gene might benefit patients with TNBC.

Companion Diagnostics and Cancer Biomarkers miR-185 Suppresses Tumor Proliferation by Directly Targeting E 2 F 6 and DNMT 1 and Indirectly Upregulating BRCA 1 in Triple-Negative Breast Cancer

MiR-205 suppressed the malignant behaviors of breast cancer cells by targeting CLDN11 via modulation of the epithelial-to-mesenchymal transition

CircRNA hsa_circ_0006220 acts as a tumor suppressor gene by regulating miR-197-5p/CDH19 in triple-negative breast cancer

MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer.

Downregulated Mir-1247-5p Associates with Poor Prognosis and Facilitates Tumor Cell Growth Via DVL1/Wnt/β-catenin Signaling in Breast Cancer

Bioinformatics Identification of Dysregulated Micrornas in Triple Negative Breast Cancer Based on Microrna Expression Profiling.

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib

Microrna-145 Functions As A Tumor Suppressor by Targeting Matrix Metalloproteinase 11 and Rab Gtpase Family 27a in Triple-Negative Breast Cancer

Tumor Suppressive Microrna-193B Promotes Breast Cancer Progression Via Targeting DNAJC13 and RAB22A.

Mir-143-3p Targeting LIM Domain Kinase 1 Suppresses the Progression of Triple-Negative Breast Cancer Cells.

MicroRNA-301b Promotes Cell Proliferation and Apoptosis Resistance in Triple-Negative Breast Cancer by Targeting CYLD

miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer.

Expression and Regulatory Function of Mirna-182 in Triple-Negative Breast Cancer Cells Through Its Targeting of Profilin 1

MicroRNA-3613-3p Functions As a Tumor Suppressor and Represents a Novel Therapeutic Target in Breast Cancer.

The Micrornas Mir-200B-3p and Mir-429-5p Target the LIMK1/CFL1 Pathway to Inhibit Growth and Motility of Breast Cancer Cells

Regulation of Cancerous Progression and Epithelial-Mesenchymal Transition by Mir-34C-3p Via Modulation of MAP3K2 Signaling in Triple-Negative Breast Cancer Cells.

Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer

MiR-940 Inhibited Cell Growth and Migration in Triple-Negative Breast Cancer.

Tumor-promoting Properties of Mir-8084 in Breast Cancer Through Enhancing Proliferation, Suppressing Apoptosis and Inducing Epithelial–mesenchymal Transition

MiR-181c Suppresses Triple-Negative Breast Cancer Tumorigenesis by Targeting MAP4K4.

Identification of Dysregulated Micrornas Associated with Diagnosis and Prognosis in Triple‑negative Breast Cancer: an in Silico Study.